David Canner Buys Shares of Inhibikase Therapeutics
David Canner increased his stake in Inhibikase Therapeutics with a purchase of 155,000 shares.
Key Points
- David Canner acquired 155,000 shares of Inhibikase Therapeutics, Inc. on June 26, 2026, with shares trading at $2.03 on Wednesday.
- Inhibikase Therapeutics has a market cap of $268 million and a 52-week range of $1.33 to $2.26.
- Analysts from Oppenheimer and Ladenburg Thalmann initiated buy ratings with price targets of $5.00 and $4.00, respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
David Canner recently bought 155,000 shares of Inhibikase Therapeutics, Inc. (NasdaqCM: IKT) on June 26, 2026. The stock traded at $2.03 on Wednesday.
Insider Buying and Selling at Inhibikase Therapeutics, Inc.
Several insiders, including David Canner, Vincent Aurentz, and Roberto Bellini, each bought 155,000 shares of Inhibikase Therapeutics on June 26, 2026. These transactions were not part of a pre-planned trading program.
Inhibikase Therapeutics, Inc. Stock Down 15.8%
Shares of NasdaqCM:IKT traded near $2.03 on Wednesday. Inhibikase Therapeutics has a market cap of approximately $268 million. The company isn't currently profitable, so it has no meaningful P/E ratio. The stock's 52-week range is between $1.33 and $2.26, with a 50-day moving average of $1.80 and a 200-day moving average of $1.71. The company's current ratio is a strong 30.14, indicating robust liquidity.
$IKT stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 10, 2026, Oppenheimer initiated coverage on Inhibikase Therapeutics with a buy rating and a $5.00 price target. Earlier in the year, on March 4, 2026, Ladenburg Thalmann also started coverage with a buy rating and a $4.00 target. The consensus among analysts is a buy rating, with a mean price target of $5.88 based on eight opinions.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Wilmington, Delaware. It focuses on developing therapies for cardiopulmonary diseases, particularly pulmonary arterial hypertension (PAH). The company is currently conducting a Phase 3 clinical trial for its leading product, IKT-001, which is designed to improve treatment for PAH while minimizing side effects.
Bottom Line
David Canner's recent purchase of Inhibikase Therapeutics shares reflects a personal investment in the company's potential. Investors often watch insider transactions for signals of confidence from within the company. However, it's important to remember that this insider purchase is just one factor among many to consider when evaluating a stock. As always, 13F filings and insider reports offer a snapshot of past actions, not necessarily current positions.
Get Inhibikase Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $IKT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.